Immunotherapy with levamisole in rheumatic diseases

Area of Science:

• Immunology
• Rheumatology
• Pharmacology

Background:

• Rheumatic diseases encompass a range of inflammatory conditions affecting joints and connective tissues.
• Levamisole, an immunomodulatory agent, has been explored for its therapeutic potential in autoimmune and inflammatory disorders.

Purpose of the Study:

• To evaluate the efficacy and safety of Levamisole in patients with rheumatoid arthritis (RA), ankylosing spondylitis (AS), and Reiter's syndrome (RS).
• To assess the immunomodulatory effects of Levamisole, including skin sensitivity and auto-antibody levels.

Main Methods:

• An open-label trial involving 23 patients diagnosed with RA, AS, or RS.
• Patients received Levamisole 150 mg daily for 4 weeks, followed by intermittent therapy (3 days/week).
• Clinical outcomes, skin antigen sensitivity, rheumatoid factor titres, lymphocyte subsets, and adverse events were monitored.

Main Results:

• Significant clinical improvement was observed in 7/9 RA patients, 4/13 AS patients, and 1/1 RS patient.
• Increased skin sensitivity to antigens was noted in 3/9 RA and 6/13 AS patients.
• Adverse reactions occurred in 13 patients, primarily allergic skin rash; severe leucopenia led to treatment withdrawal in 2 patients.

Conclusions:

• Levamisole demonstrates a definite beneficial effect in RA and a possible effect in AS and RS.
• The drug's immunomodulatory properties warrant further investigation, but potential hazardous complications like leucopenia require vigilant monitoring.